MONMOUTH JUNCTION, N.J. , Dec. 20, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the publication of results from the Company's U.S. CytoSorb Therapy in COVID-19 (CTC) retrospective registry in the peer-reviewed journal, Frontiers in Medicine.
The new publication highlights 52 critically ill COVID-19 patients from 5 major U.S. ECMO (ExtraCorporeal Membrane Oxygenation) centers who received ECMO plus CytoSorb therapy for life-threatening refractory respiratory failure under FDA EUA between April 2020 and April 2021 .1 As highlighted in topline results that were previously presented at the 40th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2021) conference in September, the primary outcome of 90-day ICU mortality was 26.9% from the initiation of CytoSorb treatment. For context, 90-day mortality among more than 6,400 adult patients in the North American cohort of the Extracorporeal Life Support Organization (ELSO) COVID-19 ECMO Registry is 50% (as of December 2021). Importantly, all 5 centers participating in the CTC registry reported that CytoSorb was easily integrated in the ECMO circuit and well-tolerated, with no unanticipated device-related adverse events.
Dr. Phillip Chan , Chief Executive Officer of CytoSorbents stated, "We are pleased that this important data set showing high survival in critically ill COVID-19 patients on CytoSorb and ECMO in the U.S. has been peer-reviewed, published, and is now available to all current and potential users globally. This is especially important, in light of increasing COVID-19 related new cases and deaths being observed around the world driven by the Delta variant, and the threat of new variants such as Omicron. To date, CytoSorb has been used in more than 7,000 critically ill COVID-19 patients in more than 30 countries worldwide, including in the U.S. under FDA Emergency Use Authorization."
Dr. Chan continued, "ECMO is a machine that pumps and oxygenates blood outside the body when a patient's lungs are so diseased that mechanical ventilation fails. Without ECMO, these patients - often considered among the sickest in the ICU - would normally die. ECMO can take the burden off of the lungs, helping them to rest. During the pandemic, this strategy has helped roughly half of the critically ill COVID-19 patients on ECMO to survive. However, ECMO does not remove the circulating inflammatory cytokines and other toxins that can contribute to ongoing injury to the lungs and other vital organs and prevent or delay healing. With Dr. Robert Bartlett , the pioneer of ECMO, our former Chief Medical Officer of 10 years, and contributing author to the CTC Registry publication, we developed the medical premise of enhanced lung rest, using CytoSorb to reduce damaging circulating inflammatory toxins while ECMO rests the lungs. The goal is to promote lung healing and recovery – a prerequisite to getting patients off of mechanical ventilation and ECMO, and to survive. The positive data from our CTC Registry, and much of the international published literature using CytoSorb and ECMO together in both COVID and non-COVID-19 patients, support this enhanced lung rest strategy, provided that it is used early enough in the disease where irreversible injury has not yet occurred."
Dr. Chan concluded, "CytoSorb and ECMO are two increasingly utilized individual critical care technologies around the world. Together, they may play a vital role in the early treatment of major unmet clinical needs such as moderate to severe lung injury, including ARDS, and as a potentially important sales growth opportunity for our Company."
1About CytoSorb and U.S. FDA Emergency Use Authorization CytoSorb® is an extracorporeal blood purification cartridge that reduces cytokines and other inflammatory mediators from the bloodstream that can contribute to severe inflammation and worsened COVID-19 illness. CytoSorb received U.S. FDA Emergency Use Authorization (EUA) in April 2020 for use in adult, critically ill COVID-19 patients with confirmed or imminent respiratory failure and is indicated to reduce cytokines in these patients. It has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The CytoSorb device is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the CytoSorb device under Section 564(b)(l) of the Act, 21 U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. More than 152,000 cumulative CytoSorb devices have been utilized to date. CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. The DrugSorb™-ATR Antithrombotic Removal System, which is based on the same polymer technology as CytoSorb, has also been granted FDA Breakthrough Designation for the removal of ticagrelor, as well as FDA Breakthrough Designation for the removal of the direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is initiating two FDA approved pivotal trials designed to support U.S. marketing approval of DrugSorb-ATR. The first is the 120-patient, 20 center STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) randomized, controlled trial evaluating the ability of intraoperative DrugSorb-ATR use to reduce perioperative bleeding risk in patients on ticagrelor undergoing cardiothoracic surgery. The second is the 120-patient, 25 center STAR–D (Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants) randomized, controlled trial, evaluating the intraoperative use of DrugSorb–ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery on direct oral anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2021 , as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact: Terri Anne Powers Vice President, Investor Relations and Corporate Communications (732) 482-9984 tpowers@cytosorbents.com
U.S. Public Relations Contact: Eric Kim Rubenstein Public Relations 212-805-3052 ekim@rubensteinpr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-announces-publication-of-us-ctc-multicenter-registry-results-using-cytosorb-in-critically-ill-covid-19-patients-on-extracorporeal-membrane-oxygenation-ecmo-301448054.html
Let’s talk about penny stocks. These are equities that trade for less than $5 per share, the very bottom of the price range. While they are priced that low for a reason – and the reasons may vary – low price in itself doesn’t mean that the stock’s fundamentals are sour. Smart investors can find some true bargains among the penny stocks, and set themselves up for outsized gains. The opportunity is linked to a simple question: Why is the company’s stock priced so low? If the answer is mainly benig
This company's market value plunged by around $8 billion in 2021, leading contrarian investors to suspect a bargain opportunity.
Amy Sussman/Invision/APTim Bergling was about to enter his second year of high school when he took his first hit of a friend’s joint. He immediately hated it. The teenager–who in a few years’ time would become internationally known as the EDM DJ Avicii–suddenly felt his throat turn scratchy and dry from the intake of marijuana, as his heart started pounding and paranoia crept in.The sensation eventually passed, but when Avicii returned home to Stockholm after his summer trip to the French Rivier
AbbVie's immunology drug Skyrizi could soon be approved in the European Union to treat patients with Crohn's disease.
Opinion: A local ER physician answers questions for the Register about antiviral pills, home tests, and who's occupying hospital beds.
There were 592 new, confirmed cases of COVID-19 in Monroe County for the week of December 16-22.
Not even the government is sure whether you'll end up paying more or paying less.
The U.S. Centers for Disease Control and Prevention is investigating more cruise ships due to new cases of COVID-19 as the omicron variant drives extremely high infection levels in the industry hub of Florida. The CDC said 88 vessels are now either under investigation or observation, but it did not specify how many COVID-19 cases have been reported. Four other vessels are also being monitored by the CDC as well.
WASHINGTON - Fareha Ahmed had been cautious since the beginning of the pandemic. She had eaten in restaurants only three times. She and her husband were vaccinated and boosted, and their 7-year-old got vaccinated in November as soon as he was eligible. In mid-December, Ahmed, 39, who lives in Washington, D.C., met a former colleague for an outdoor lunch. A few days later, the family attended an indoor gathering for the first time with other families, to bake Christmas cookies. Then covid caught
Photo Illustration by The Daily Beast/GettyThe U.S. Food and Drug Administration has granted emergency-use authorization to two prescription COVID pills that patients with mild-to-moderate infections can take at home and that, to varying degrees, can prevent the worst outcomes. Serious illness. Hospitalization. Death.Doctors were counting on the new pills, from New Jersey pharma Merck and Pfizer in New York, to help keep people out of hospitals as the Delta and Omicron lineages of the SARS-CoV-2
With the omicron COVID variant proving more transmissible than any other, there's a very good chance you'll catch it, no matter how careful you are. To keep you safe, Dr. Tatiana Prowell, an Associate Professor of Oncology at Johns Hopkins School of Medicine, who serves people with COVID-19, tweeted a viral thread to lay out exactly what you should do the minute you or someone you know has symptoms (and she described the symptoms, too). Read on for the exact steps—and to ensure your health and t
via YouTubeAn Italian anti-vaxxer and COVID-denier who sparked outrage after declaring himself a “plague spreader” and boasting about how he walked around sick and maskless in a supermarket has died of COVID-19, according to local media reports.Maurizio Buratti, also known as Mauro from Mantua, died in a Verona hospital Monday, just a few weeks after being hospitalized. He was 61.Buratti’s condition took a turn for the worse, perhaps unsurprisingly, after he called in to the Zanzara radio progra
The CDC has changed its recommendations for COVID isolation and quarantine. Dr. Celine Gounder explains how to navigate the new guidelines to protect against the Omicron case surge.
The pandemic may have brought these companies to prominence, but there's much more to the story.
A UAB investigated covid treatment from Mereo BioPharma Group shows positive results in early clinical trial.
The No Surprises Act, which is putting an end to surprise medical bills from out-of-network providers, is scheduled to go into effect on Jan. 1, 2022. According to federal estimates, it will apply to...
What happens when you transition from a plant-based diet to an omnivorous one? We asked a dietitian to find out.
The Centers for Disease Control and Prevention made significant revisions to its omicron new-case estimates. In new data released Tuesday, the federal agency said new cases of omicron accounted for just 22.5% of new cases for the week ending Dec. 18, not 73% as originally estimated. For the week ending Dec. 25, omicron accounted for 58.6% of new coronavirus cases compared to 41.1% of delta, the CDC said.
A new paper by researchers at the University of Southern California and RAND Corporation sheds light on other advantages of being vaccinated.
France's government is forging ahead with efforts to increase pressure on unvaccinated people to get coronavirus shots, as the country reported 208,000 new COVID-19 cases Wednesday — a record fueled by the omicron variant.